Related Experiment Video
Updated: Jun 18, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care
Aritro Nath1, Jyoti Malhotra2, Isa Mambetsariev1
1Department of Medical Oncology & Therapeutics Research, City of Hope, 1500 E Duarte Rd., Duarte, CA 91010, USA.
Abstract:
Tumor heterogeneity and evolution constrain NSCLC immunotherapy, leading to variable and often short-lived responses. This commentary discusses the ARPA-H ADAPT program and IMMUNO-BIOMAP trial, which longitudinally profile tumors and the microenvironment to identify resistance mechanisms in real time and enable adaptive, biomarker-guided, personalized treatment strategies.
Related Concept Videos
Tumor Immunotherapy
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
